Nuvo Pharmaceuticals Inc. (NRI.TO) Stock Forecast, Price & News

+0.30 (+0.86 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: C$35.28
50-Day Range
MA: C$26.04
52-Week Range
Now: C$35.28
Average Volume19,371 shs
Market CapitalizationC$401.71 million
P/E RatioN/A
Dividend YieldN/A
Nuvo Pharmaceuticals Inc., a healthcare company, provides prescription and non-prescription products for pain, allergy, and dermatology in the United States, Canada, Europe, and internationally. The company operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for the treatment of migraine; Resultz, a non-prescription product intended to kill head lice and remove their eggs from hair; and Suvexx/Treximet, a medicine for migraine. The company also provides Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid; Vimovo for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; Yosprala for secondary prevention of cardiovascular and cerebrovascular events; and Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch applied prior to painful medical procedures, such as venous access, blood draws, needle injections and minor dermatologic surgical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesC$76.09 million
Cash FlowC$73.57 per share
Book ValueC$1.63 per share



Market CapC$401.71 million
Next Earnings DateN/A
OptionableNot Optionable


Miravo Healthcare™ to Present at Upcoming Investor Conferences
April 9, 2021 |  markets.businessinsider.com
Miravo Healthcare to present at the Q1 Virtual Investor Summit
March 11, 2021 |  markets.businessinsider.com
Nuvo Pharmaceuticals® Announces Third Quarter 2020 Results
November 16, 2020 |  finance.yahoo.com
Nuvo Pharmaceuticals Inc. Regis (23N.SG)
October 10, 2020 |  in.finance.yahoo.com
See More Headlines


Overall MarketRank

0.83 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.30 (+0.86 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NRI News and Ratings via Email

Sign-up to receive the latest news and ratings for NRI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) Frequently Asked Questions

Is Nuvo Pharmaceuticals Inc. (NRI.TO) a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvo Pharmaceuticals Inc. (NRI.TO) in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nuvo Pharmaceuticals Inc. (NRI.TO) stock.
View analyst ratings for Nuvo Pharmaceuticals Inc. (NRI.TO)
or view top-rated stocks.

What stocks does MarketBeat like better than Nuvo Pharmaceuticals Inc. (NRI.TO)?

Wall Street analysts have given Nuvo Pharmaceuticals Inc. (NRI.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nuvo Pharmaceuticals Inc. (NRI.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Nuvo Pharmaceuticals Inc. (NRI.TO)'s stock price been impacted by Coronavirus (COVID-19)?

Nuvo Pharmaceuticals Inc. (NRI.TO)'s stock was trading at C$0.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NRI stock has increased by 4,309.4% and is now trading at C$35.28.
View which stocks have been most impacted by COVID-19

Who are Nuvo Pharmaceuticals Inc. (NRI.TO)'s key executives?

Nuvo Pharmaceuticals Inc. (NRI.TO)'s management team includes the following people:
  • Mr. Robert Paul Harris, Exec. Chairman (Age 65, Pay $594.83k)
  • Mr. Jesse F. Ledger, Pres & CEO
  • Dr. Bernard Joseph Chiasson, VP of Operations & Chief Scientific Officer
  • Ms. Katina K. Loucaides M.Sc., LL.B, VP, Corp. Sec. & Gen. Counsel
  • Ms. Mary-Jane E. Burkett C.A., CPA, CPA, -CA, HBA, VP & CFO (Leave of Absence)
  • Ms. Kelly Demerino C.A., CPA, Interim Chief Financial Officer
  • Mr. Renny Ho, Investor Relations Officer
  • Mr. Patrick Gushue, Director of Marketing & National Sales
  • Dr. J. Zev Shainhouse, Medical Director
  • Mr. Calogero Lunetta, VP of Manufacturing

Who are some of Nuvo Pharmaceuticals Inc. (NRI.TO)'s key competitors?

What other stocks do shareholders of Nuvo Pharmaceuticals Inc. (NRI.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuvo Pharmaceuticals Inc. (NRI.TO) investors own include (AVO.TO) (AVO), Allena Pharmaceuticals (ALNA), Citius Pharmaceuticals (CTXR), (SPE.TO) (SPE), Bombardier, Inc. Class B (BBD.B), Cameco (CCO), Crescent Point Energy (CPG), First Quantum Minerals (FM), Kopin (KOPN) and Leap Therapeutics (LPTX).

What is Nuvo Pharmaceuticals Inc. (NRI.TO)'s stock symbol?

Nuvo Pharmaceuticals Inc. (NRI.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NRI."

How do I buy shares of Nuvo Pharmaceuticals Inc. (NRI.TO)?

Shares of NRI and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Nuvo Pharmaceuticals Inc. (NRI.TO)'s stock price today?

One share of NRI stock can currently be purchased for approximately C$35.28.

How much money does Nuvo Pharmaceuticals Inc. (NRI.TO) make?

Nuvo Pharmaceuticals Inc. (NRI.TO) has a market capitalization of C$401.71 million and generates C$76.09 million in revenue each year.

How many employees does Nuvo Pharmaceuticals Inc. (NRI.TO) have?

Nuvo Pharmaceuticals Inc. (NRI.TO) employs 99 workers across the globe.

What is Nuvo Pharmaceuticals Inc. (NRI.TO)'s official website?

The official website for Nuvo Pharmaceuticals Inc. (NRI.TO) is www.nuvopharmaceuticals.com.

Where are Nuvo Pharmaceuticals Inc. (NRI.TO)'s headquarters?

Nuvo Pharmaceuticals Inc. (NRI.TO) is headquartered at 6733 Mississauga Road, Suite 800, MISSISSAUGA, ON L4T 4H4, Canada.

How can I contact Nuvo Pharmaceuticals Inc. (NRI.TO)?

Nuvo Pharmaceuticals Inc. (NRI.TO)'s mailing address is 6733 Mississauga Road, Suite 800, MISSISSAUGA, ON L4T 4H4, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-6736980.

This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.